VRTX · Earnings call · 2026Q3T · Full report

Acquisition / Partnership / Divestiture

VERTEX PHARMACEUTICALS INC / MA · 2026-11-02 · Importance 56 · Surprise 60

Vertex closed its acquisition of Crinetics at the beginning of September 2026, adding Palsonify revenue and making rare endocrinology its fourth commercial pillar. Crinetics contributed $10 million of September revenue and approximately $24 million for the full third quarter. Management’s revised full-year 2026 forecast includes $40 million to $50 million of Crinetics revenue and approximately $250 million of Crinetics operating and integration-related expenses. The acquisition was partly funded with $4.5 billion of term loans, and management said integration was underway across commercial, clinical, and preclinical programs.

Key facts

• Q3 2026 acquired IPR&D expense was $41 million, including a $28 million upfront payment for a new business development agreement with AbCellera.
• Vertex incurred approximately $50 million in Q3 non-operating costs associated with Crinetics transaction financing.
• Q3 2026 revenue included $10 million from Crinetics following the acquisition close.